Strategic investments strengthen resilience and service capabilities for innovative injectable therapies
· First of ten additional commercial manufacturing lines already operational
· Continued expansion of global filling capabilities
· Ongoing investments strengthen flexibility, resilience, and supply security
Ravensburg, September 28, 2026: Vetter, a leading Contract Development and Manufacturing Organization (CDMO), continues to expand its commercial fill-and-finish network to further strengthen its global manufacturing operations and support the evolving needs of pharma and biotech customers. The company’s long-term investment program includes the addition of ten more commercial filling lines.
Seven of the ten planned manufacturing lines
are being implemented across Vetter’s existing sites. This phased rollout will
make additional manufacturing resources available over the coming years. The
first new line, designed to fill pre-sterilized syringes, recently became
operational, and a second line is expected to follow by the end of 2026.
Another five lines for aseptic production are planned through 2028. Looking
ahead, the final three lines are planned for Vetter’s new commercial site in
Saarlouis, Germany, which is expected to become operational by 2031.
“Pharma and biotech companies seek
partners with a proven track record, operational expertise, and the
capabilities to support their current and future drug products,” states
Managing Director Henryk Badack. “This demand is reflected in our strategy for
sustainable growth. Through our ongoing investments, we are expanding our
global manufacturing resources and strengthening our ability to support
customers throughout the lifecycle of their products in international markets.”
Continued investment in Vetter’s broader
operational infrastructure accompanies the expansion of its manufacturing
capacity. Current initiatives include expanding compounding, pharmaceutical
storage, and visual inspection capabilities, as well as implementing advanced
cleanroom technology and increased automation and digitalization.
“Our phased approach enables us to make
additional capacity available while systematically expanding our global
production network,” explains Managing Director Carsten Press. “These
investments provide customers with scalable operations, well-managed supply
chains, and high-quality aseptic manufacturing to support their long-term
growth.”
Vetter will be exhibiting at CPHI
Milan from October 6 to 8, 2026, at booth 6A52,
where company representatives will engage with customers and industry
stakeholders to discuss current and future project requirements.
© Vetter Pharma International
GmbH: The latest filling line at Vetter’s commercial facility
in Langenargen, Germany
Find the Vetter press kit and more
background information here.
About
Vetter Vetter
is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters
in Ravensburg, Germany, and production facilities in Germany, Austria, and the
US. As a global player, the independent pharmaceutical service provider is also
present in the Asia-Pacific markets of Japan, China, South Korea, and
Singapore with sales locations. Around the world renowned pharma and
biotech companies benefit from decades of experience, high quality,
modern technologies, reliability, and commitment of its
7,400 employees. In close collaboration with its customers, the Vetter
team helps enable the supply to patients all over the world with medicines,
many of which are vital. The CDMO provides support from drug product
development through clinical and commercial filling to a wide range of assembly
and packaging services for vials, syringes, and cartridges. With innovative
approaches, Vetter develops prefilled drug-delivery systems together with its
customers to continuously improve patient safety, comfort, and compliance.
Vetter takes responsibility for sustainable practices and operates as
a socially and ethically responsible corporate citizen. The CDMO is a member of
the UN Global Compact and Science Based Target
initiative (SBTi) and received platinum status in the
renowned EcoVadis ranking. Multiple awards such as the CDMO
Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition of Best
Managed Company emphasize Vetter’s commitment to sustainable business.
Founded in Ravensburg in 1950, the company remains family-owned to
this day. For more information, visit www.vetter-pharma.com and follow Vetter
on LinkedIn.
Contact Vetter
Pharma International GmbH Markus
Kirchner Corporate
Spokesperson / Media Relations Eywiesenstrasse 5 88212
Ravensburg Germany Phone:
+49 (0)751-3700-3729 E-mail: PRnews@vetter-pharma.com
